









Markets
/
Stocks
/
nasdaq-arqt
/

Arcutis Biotherapeutics Inc

ARQT

View Detailed Chart

14.290USD

-0.290-1.99%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

1.70BMarket Cap

LossP/E TTM



Arcutis Biotherapeutics Inc

14.290

-0.290-1.99%

Overview Company Financials

Financials

Intraday

30m

Today

-1.99%

5 Days

-3.84%

1 Month

+3.40%

6 Months

+12.61%

Year to Date

+2.58%

1 Year

+54.49%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

BUY

Current Rating

21.250

Target Price

48.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Arcutis Biotherapeutics Inc

ARQT

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(2)

Buy(2)

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.182

Neutral

RSI(14)

46.016

Neutral

STOCH(KDJ)(9,3,3)

26.536

Sell

ATR(14)

0.664

Low Volatility

CCI(14)

-134.400

Sell

Williams %R

89.812

Oversold

TRIX(12,20)

0.208

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

14.680

Sell

MA10

14.708

Sell

MA20

14.781

Sell

MA50

14.179

Buy

MA100

14.472

Sell

MA200

13.319

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Ticker SymbolARQT

CompanyArcutis Biotherapeutics Inc

CEOMr. Todd Franklin Watanabe

Websitehttps://arcutis.com/